08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Lomitapide: Additional Phase III data

Additional data from 23 evaluable patients who completed 78 weeks of treatment in a single-arm, open-label, international Phase III trial showed that oral lomitapide titrated up to 60 mg/day reduced mean LDL-C by 38.4% from...
07:00 , Sep 12, 2011 |  BioCentury  |  Product Development

Reviving CETP

Evidence is accumulating that the next generation of CETP inhibitors may be able to avoid the off-target effects that doomed Pfizer Inc. 's torcetrapib. Roche reported Phase IIb data in late August showing its dalcetrapib...
07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

Lomitapide: Additional Phase III data

Data from a completer analysis of 23 evaluable patients in a single-arm, open-label, international Phase III trial showed that oral lomitapide titrated up to 60 mg/day reduced mean LDL-C by 50.2% from baseline to week...
07:00 , Jun 7, 2010 |  BioCentury  |  Emerging Company Profile

LipimetiX: Aping APOE

LipimetiX LLC is hoping to bypass defective LDL receptors in the livers of patients with heritable hyperlipidemia with its mimetics of apolipoprotein E , a protein that can target two additional hepatic receptors capable of...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

GFT505: Phase II data

In the 28-day, double-blind, international Phase IIa GFT505-2083 trial in 97 pre-diabetics with atherogenic dyslipidemia and abdominal obesity, 80 mg/day oral GFT505 met the co-primary endpoints and multiple secondary endpoints. On the co-primary endpoints, GFT505...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Lomitapide: Additional Phase III data

Additional data from an ongoing, open-label Phase III trial in 14 evaluable patients treated for at least 26 weeks showed that lomitapide titrated up to 60 mg/day reduced mean LDL-C by 49%. Average baseline LDL-C...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

Lomitapide: Interim Phase III data

Interim data from 10 evaluable patients treated for at least 6 months in an ongoing, open-label Phase III trial showed that lomitapide titrated up to 60 mg/day reduced mean LDL-C by 44%. Average baseline LDL-C...
08:00 , Dec 22, 2008 |  BC Week In Review  |  Clinical News

GFT505: Phase II start

Next half, Genfit will start a double-blind, placebo-controlled, international Phase II trial (Study 2083) to evaluate 80 mg/day of oral GFT505 in 90 patients with abdominal obesity for 28 days. Genfit S.A. (Euronext:ALGFT), Lille, France...
08:00 , Dec 18, 2008 |  BC Innovations  |  Distillery Techniques

This week in techniques

The Distillery: Techniques Approach Summary Licensing status Publication and contact information Markers Assessment of pulmonary arterial hypertension (PAH) risk in sickle cell disease patients using plasma apolipoproteins Apolipoprotein levels in plasma samples could potentially predict...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

AEGR-733: Preliminary Phase III data

Preliminary data from an ongoing, open-label, Phase III trial in 25 patients showed that AEGR-733 titrated up to 60 mg/day was well tolerated and reduced LDL-C by >50% in the majority of patients that reached...